AI Science Tracker
EN

A risk prediction model for neovascular glaucoma secondary to proliferative diabetic retinopathy based on Boruta feature selection and random forest

The Second Clinical Medical College of Jinan University, Shenzhen Eye Hospital, Shenzhen, Guangdong, China · 27 Jun 2025 · medicine

Discovery

A risk prediction model for neovascular glaucoma secondary to proliferative diabetic retinopathy based on Boruta feature selection and random forest

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: A random-forest model predicted neovascular glaucoma risk in diabetic-retinopathy patients with reported diagnostic metrics. The result is limited to the reported study population and evaluation; the source does not establish transfer to other populations or improved clinical outcomes.

Technology: Random-forest risk-prediction model

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Random-forest risk-prediction model
Limitation / still unknown
The study does not establish improved patient outcomes or generalization beyond the evaluated setting.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12247303/ · https://doi.org/10.3389/fcell.2025.1604832 · https://pubmed.ncbi.nlm.nih.gov/40655951/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.